Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan일본 의료 센터에서 BNT162b2 mRNA COVID-19 백신의 효과 및 돌파구에 대한 실제 증거Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Asia Asian BNT162b2 BNT162b2 vaccine breakthrough COVID-19 vaccine delta variant demonstrated Effectiveness Effectiveness. Evidence evidence of hospital hygiene Infection infection control Japan measure mRNA of BNT162b2 Population populations Public hygiene Regulation required retrospective cohort study SARS-CoV-2 Spread Tokyo vaccination Vaccine variant while [DOI] 10.1080/21645515.2021.1984124 PMC 바로가기 [Article Type] Article
COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimodArticle Published on 2022-12-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, [키워드] binding antibody unit BNT162b2 mRNA BNT162b2 mRNA vaccine booster dose collected Control COVID-19 COVID-19 vaccine dose expressed fingolimod HCs humoral Humoral response IgG IgG antibody IgG level Laboratory mRNA mRNA vaccine Multiple multiple sclerosis Ocrelizumab Ocrelizumab. of BNT162b2 Patient positive predict quantified reported SARS-CoV-2 sclerosis serum sample severe adverse event socio-demographic threshold Tolerability treated Trimeric spike protein Vaccine vaccine dose variable [DOI] 10.1007/s00415-022-11296-4 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyArticle Published on 2022-12-012022-10-06 Journal: Lancet Reg Health Am [Category] 진단, [키워드] age All participant anti-SARS-CoV-2 BNT162b2 BNT162b2 vaccine booster Care cohort study CoronaVac COVID-19 determine dose effective end point General population groups Heterologous heterologous vaccine homologous humoral immune response IFN-γ IgG antibody IL-2 inactivated kidney liver median Medicine more difficult mRNA mRNA vaccine neutralising antibody not differ of BNT162b2 outcome Patient priming proportion Prospective prospective cohort study recipient recipients Red SARS-CoV-2 SARS-CoV-2 vaccine School secondary secreting significantly significantly higher solid organ solid organ transplant SOT T-cell T-cell responses vaccination Vaccine vaccine immunogenicity. women [DOI] 10.1016/j.lana.2022.100371 PMC 바로가기 [Article Type] Article
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants variants. [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study단일 의료 시스템에서 의료 종사자들 사이에서 BNT162b2 백신 접종 후 SARS-CoV-2 스파이크 단백질에 대한 부작용과 면역 반응 사이의 연관성: 전향적 관찰 코호트 연구Observational Study Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 임상, 진단, [키워드] administration Adverse Adverse reaction Anti-spike IgG antibody anti-spike IgG level Antibody titer association Asthma BNT162b2 BNT162b2 vaccine conducted COVID-19 Cutoff determine Factor first dose healthcare healthcare worker help humoral humoral immune response Humoral response IgG IgG level immune response information Local majority median median age mRNA mRNA vaccine of BNT162b2 participant Participants prospective observational cohort reaction recipients recruited reported SARS-CoV-2 anti-spike IgG SARS-CoV-2 spike protein second dose significantly higher systemic adverse reactions Systemic adverse reactions. systemic reaction vaccination Vaccine was collected were measured with COVID-19 women [DOI] 10.1080/21645515.2022.2048559 PMC 바로가기 [Article Type] Observational Study
Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort studyArticle Published on 2022-11-032022-11-16 Journal: Scientific Reports [Category] SARS, 변종, [키워드] Ad26.COV2.S vaccine Alpha Apulia calculate ChAdOx1-S Cohort combined use conducted COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccination programme Cox regression model death deaths Delta variants dominant Effect Effectiveness Effects Electronic health record eligible estimate hazard ratio Hospital admission hospitalisation infections Italy mRNA-1273 of BNT162b2 Older outcome positive Protective reduced retrospective cohort study SARS-CoV-2 SARS-CoV-2 infections study period subject vaccination Vaccine variant variants waned were used yielding [DOI] 10.1038/s41598-022-23235-4 PMC 바로가기
Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseasesArticle Published on 2022-11-022022-11-15 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, [키워드] acute respiratory syndrome Administered Anti-RBD IgG antibody Antibody Response approval baseline biologic BNT162b2 mRNA BNT162b2 mRNA vaccine children Cohort cohort of patient Combined therapy coronavirus coronavirus disease COVID-19 disease Disease activity domain dose dose regimen effective elevated evaluated humoral Humoral response IgG antibody immunogenicity immunomodulatory IQR Local median mRNA vaccine of BNT162b2 paediatric rheumatic disease. pandemic Patient RBD receiving rheumatic disease safety profile SARS-CoV-2 second dose significantly lower Spike protein study period systemic side effect titre treated Treatment Vaccine were measured [DOI] 10.1093/rheumatology/keac140 PMC 바로가기
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody neutralization Antibody titre B.1.1.529 BNT162b2 booster Breakthrough infection convalescent CoronaVac COVID-19 detectable dose elicited geometric GMT Immune escape individual Infection less natural infection neutralization neutralizing antibody Neutralizing antibody response of BNT162b2 omicron Omicron, Neutralization plaque reduction neutralization PRNT reduction relative SARS-CoV-2 susceptible Transmissibility vaccinated individual vaccination Vaccine vaccine. Vaccines virus viruses VoC wild- type WT virus [DOI] 10.1016/j.jcv.2022.105273 PMC 바로가기